Personalized Metabolic Responses to Rapid, Slow and Resistant Starch

Launched by CHALMERS UNIVERSITY OF TECHNOLOGY · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how different types of starch in food affect people with overweight and obesity. Specifically, it will study three kinds of starch: resistant starch, slow digestible starch, and rapid digestible starch. Over 12 weeks, participants will try each type of starch in a specific order, with breaks in between where they can eat their regular diet. The researchers will gather information from blood, saliva, and stool samples, along with monitoring blood sugar levels and asking participants about their eating habits, lifestyle, and overall well-being.

To take part in this study, participants need to be men or post-menopausal women aged 30 to 70 who are overweight (with a body mass index between 27 and 40) and have a stable weight. They should also be willing to follow the diet plans provided and be able to manage the monitoring devices used during the trial. However, certain individuals, like those with diabetes or recent heart problems, or those who have had major gastrointestinal surgeries, will not be eligible. This study aims to better understand how our bodies react to different starches, which could help improve dietary recommendations for weight management and overall health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and post-menopausal women
• • Age 30-75 years
• • BMI 27-40 kg/m2
• • Waist circumference \> 102/88 cm for men/women
• • Weight stable during previous 3 months (± 3 kg)
• • Willingness to consume the intervention diets
• • Ability to deal with the monitoring devices
• • Medications stable for the previous 14 days
• • Signed informed consent
• Exclusion Criteria:
• • Cardiovascular events (myocardial infarction or stroke) during the previous 6 months
• • Diagnosis of diabetes (any type) or use of any drug who can interfere with glucose homeostasis (i.e., metformin, incretin analogues, SGLT-2 inhibitors)
• • History of stomach or gastrointestinal conditions (inflammatory bowel disease, Crohn's disease, malabsorption, etc.)
• • Colostomy, bowel resection, bariatric surgery or other major gastrointestinal surgery
• • Renal or liver failure (creatinine \<1.7 mg/dl and alanine aminotransferase/aspartate aminotransferase \< 2 times than normal values, respectively)
• • Anemia (hemoglobin below the age and sex specific normal reference ranges at screening)
• • Blood donation (or participation in a clinical study with blood sampling) within 30 days prior to inclusion
• • Having been treated with antibiotics within the past 3 months or planning to undergo treatment during the study period.
• • Habitual use of probiotic/prebiotic supplements or foods enriched in probiotics
• • Celiac disease
• • Vegan/vegetarian diet (or a diet incompatible with protocol diets)
• • Intense physical activity regimen (\> 7 h/week of moderate intensity or \> 3 h/week of high intensity)
• • History of drug or alcohol abuse
• • Not able to understand written and spoken Swedish
• • Any other reason for lack of suitability for participation in the trial, as judged by the principal investor or co-principal investigator